Health and Healthcare

Eli Lilly : LLY

All Eli Lilly Articles

655 Articles

Chris Lange | Jun 27, 2017 at 8:45 AM EDT

Short Sellers Run for Cover From Major Pharma

The June 15 short interest data have been compared with the previous figures, and short interest in most of these…

Chris Lange | Jun 12, 2017 at 8:55 AM EDT

Short Sellers Grow More Selective on Major Pharma

The May 31 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Jun 2, 2017 at 1:35 PM EDT

15 Companies Bracing for Big ASCO Reactions

24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could…

Chris Lange | May 27, 2017 at 8:40 AM EDT

Big Pharma Has Big Catalysts Coming for the Rest of 2017

A new Deutsche Bank research report focuses on the big capitalization pharmaceutical stocks and the upcoming catalysts and news flow…

Chris Lange | May 25, 2017 at 9:45 AM EDT

Major Pharma Short Interest Surges

The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | May 24, 2017 at 1:55 PM EDT

What to Expect From Eli Lilly at ASCO

24/7 Wall St. takes a look at Eli Lilly, and what Credit Suisse sees happening for this pharma giant at…

Paul Ausick | May 15, 2017 at 11:35 AM EDT

Top Credit Suisse Pharma Picks Ahead of Catalysts

Credit Suisse provided its outlook for several large-cap pharmaceutical stocks Monday morning. The analyst has three top picks to consider.

Jon C. Ogg | May 11, 2017 at 11:00 AM EDT

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

It is no secret that pharma and biotech shares have had to deal with at least some headwinds over the…

Chris Lange | May 10, 2017 at 9:00 AM EDT

Short Interest in Major Pharma Shrinks

The April 28 short interest data have been compared with the previous figures, and short interest moves in these selected…

Lee Jackson | May 5, 2017 at 8:20 AM EDT

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

JPMorgan has made the case that the best place for investors to look when considering large cap drug stocks is…

Jon C. Ogg | Apr 27, 2017 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Amex, Cisco, Eli Lilly, First Solar, McDonald’s, Microsoft, US Steel and More

The top analyst upgrades, downgrades and other research calls on Thursday include American Express, Cisco, Eli Lilly, First Solar, McDonald's,…

Chris Lange | Apr 26, 2017 at 8:25 AM EDT

Short Sellers Can’t Make Up Their Minds on Major Pharma

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected…

Jon C. Ogg | Apr 17, 2017 at 10:20 AM EDT

FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte

When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and…

Lee Jackson | Apr 17, 2017 at 10:00 AM EDT

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and…

1 … 24 25 26 27 28 … 44

Eli Lilly : LLY

All Eli Lilly Articles

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

What to Expect From Eli Lilly at ASCO

Top Credit Suisse Pharma Picks Ahead of Catalysts

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

Short Interest in Major Pharma Shrinks

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

Top Analyst Upgrades and Downgrades: Amex, Cisco, Eli Lilly, First Solar, McDonald’s, Microsoft, US Steel and More

Short Sellers Can’t Make Up Their Minds on Major Pharma

FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

Most Income Investors Have Never Heard of the Bond ETF Paying 8 Percent for Betting Against Natural Disasters

Tesla Vs. SpaceX: Here’s Which Will Outperform the Other by the End of July

Early Snowflake Investor Nails a 50% Rebound That May Only Be Warming Up

A 73-Year-Old With $1.4 Million Faces a $53,000 RMD, Plus the Bracket Jump Nobody Warned Them About

The Real Cost of Retiring to Scottsdale, Arizona, at 65 on $950,000 Stress Free

Most Income Investors Have Never Heard of the Bond ETF Paying 8 Percent for Betting Against Natural Disasters

Tesla Vs. SpaceX: Here’s Which Will Outperform the Other by the End of July

Eli Lilly : LLY

All Eli Lilly Articles

Short Sellers Run for Cover From Major Pharma

Short Sellers Grow More Selective on Major Pharma

15 Companies Bracing for Big ASCO Reactions

Top Presentations to Look for at ASCO

Big Pharma Has Big Catalysts Coming for the Rest of 2017

Major Pharma Short Interest Surges

What to Expect From Eli Lilly at ASCO

Top Credit Suisse Pharma Picks Ahead of Catalysts

Merck’s Accelerated Keytruda Lung Cancer Approval Creates 3 Moves

Short Interest in Major Pharma Shrinks

JPMorgan Has 3 Top Pick Large Cap Pharmaceuticals to Buy for the Rest of 2017

Top Analyst Upgrades and Downgrades: Amex, Cisco, Eli Lilly, First Solar, McDonald’s, Microsoft, US Steel and More

Short Sellers Can’t Make Up Their Minds on Major Pharma

FDA Delivers Big Rheumatoid Athritis Disappointment for Eli Lilly and Incyte

Top Dividend Pharmaceutical Stocks Safe Bet for Rest of 2017

Most Income Investors Have Never Heard of the Bond ETF Paying 8 Percent for Betting Against Natural Disasters

Tesla Vs. SpaceX: Here’s Which Will Outperform the Other by the End of July

Early Snowflake Investor Nails a 50% Rebound That May Only Be Warming Up

Featured Reads

A 73-Year-Old With $1.4 Million Faces a $53,000 RMD, Plus the Bracket Jump Nobody Warned Them About

The Real Cost of Retiring to Scottsdale, Arizona, at 65 on $950,000 Stress Free